Northland Capital Initiates Coverage on Endo Intl (NASDAQ:ENDP). What May be Next?


Why Has Northland Capital Given Endo Intl (NASDAQ:ENDP) a $67 Price Target

In an analyst note released on Wednesday morning, Northland Capital analyst has today commenced coverage coverage for Endo Intl (NASDAQ:ENDP) shares with a “Market Perform” rating. The target price per share is $67.

From a total of 17 analysts covering Endo International plc (NASDAQ:ENDP) stock, 13 rate it a ”Buy”, 0 a “Sell”, and 7 a ”Hold”. This means that 65% of the ratings are positive. The highest target price is $115 while the lowest target price is $55. The mean of all analyst targets is $84.06 with a 33.96% above today’s ($58.39) stock price. Endo International plc was the topic of 16 analyst reports since August 11, 2015 according to the firm StockzIntelligence Inc. Mizuho downgraded shares on November 16 to “Neutral” rating. Deutsche Bank maintained ENDP stock in a recent report from November 6 with “Buy” rating.

Approximately 690,019 shares of stock traded hands. Endo International plc – Ordinary Shares (NASDAQ:ENDP) has declined 29.96% since May 6, 2015 and is downtrending. It has underperformed by 29.17% the S&P500.

The overall sentiment of institutions has decreased to 1.29 in Q2 2015. Its down 0.49, from 1.78 in 2015Q2. The ratio is negative, as 61 institutions have sold all the shares of Endo International plc – Ordinary Shares that they owned while 103 funds have taken shares off the table. 41 funds have purchased shares for the first time while 171 added to their positions. These institutions now hold 217.24 million shares or 18.59% more than the 183.19 million shares they owned in 2015Q2.

The Fund Michael & Susan Dell Foundation currently is holding shares equating to 20.89% of its total portfolio in Endo International plc – Ordinary Shares representing a total of 413,466 shares. Another fund,Aravt Global Llc, is holding a total of 1.73 million shares equating to 10.27% of their holdings. Additionally, Ratan Capital Management Lp has a 562,699 share stake in Endo International plc – Ordinary Shares which represents 8.52% of their total portfolio. The Fund, Permian Investment Partners Lp, based out of New York, has also built up a stake in the stock, which represents a total of 7.98% of their total portfolio. Finally Tiger Legatus Capital Management Llc, a fund which is based in the state of New York reported a total holdings of 320,000 shares.

According to Zacks Investment Research, “Endo International plc is a global specialty healthcare company. It develops, manufactures, markets, and distributes quality branded pharmaceutical and generic products as well as medical devices. Endo offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel for pain, urology, endocrinology, and oncology. The company also provides non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and hypertension markets. Endo International plc, formerly known as Endo Pharmaceuticals Holdings Inc., is headquartered in Dublin, Ireland.” Get a free copy of the Zacks research report on Endo International plc – Ordinary Shares (ENDP).